Teva Leads Generic Rivals In First-To-File ANDAs By A Long Shot
Executive Summary
Teva has submitted 13 ANDAs with first-to-file opportunities to FDA this year, while rivals Mylan, Endo, Sandoz and Indian firm Hetero each have filed two ANDAs with FTFs, according to public data released by the agency and further analyzed by Teva.
You may also be interested in...
Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches
The world’s generic drug leader has cemented its leadership position for the foreseeable future with the acquisition of Allergan’s generics business. Management outlined how it plans to grow the combined business by taking advantage of its size during an investor briefing.
GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
Generics industry and FDA have resolved remaining issues regarding financing of user fee program.
Mylan Sees A Difference In Having Generic Drug User Fees
FDA is pushing forward with its review of Mylan’s ANDA for generic Advair, according to the company, which is gaining confidence that the application could receive a first round approval. The experience for that application, which has a generic drug user fee, is a clear contrast to the firm's experience with its pre-GDUFA Copaxone filing.